Autoantibodies against α-synuclein inhibit its aggregation and cytotoxicity
Carmen Noelker1, Florian Seitz1, Annekathrin Sturn1
1Department of Neurology, Philipps-University Marburg, Rudolf-Bultmann Strasse 8, 35033, Marburg, Germany.
Journal of Autoimmunity
|March 4, 2025
Summary
Naturally occurring autoantibodies against alpha-synuclein (α-Syn) were isolated and characterized. These autoantibodies inhibit α-Syn fibril formation and reverse its toxicity, suggesting potential Parkinson
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Alpha-synuclein (α-Syn) aggregates form Lewy bodies, a hallmark of Parkinson's disease (PD).
- Naturally occurring autoantibodies against α-Syn (α-Syn-nAbs) have recently been identified.
- Understanding the properties and functions of these α-Syn-nAbs is crucial for PD research.
Purpose of the Study:
- To isolate and characterize naturally occurring autoantibodies against α-Syn (α-Syn-nAbs).
- To determine the binding characteristics, epitope, and functional effects of these α-Syn-nAbs.
- To explore the potential therapeutic implications of α-Syn-nAbs in Parkinson's disease.
Main Methods:
- Isolation of α-Syn-nAbs from intravenous Immunoglobulin (IVIg) using an α-Syn affinity column.
- Characterization of binding capacity via ELISA, Western blotting, and immunoprecipitation.
- Analysis of binding affinity using surface plasmon resonance (Biacore) and epitope mapping via peptide arrays.
- In vitro functional assays including toxicity and fibrillation inhibition using neuroblastoma cells.
Main Results:
- α-Syn-nAbs demonstrated strong binding to α-Syn, with detailed affinity analysis performed.
- The critical binding epitope was mapped to a specific sequence within the non-amyloid component (NAC)-Region of α-Syn.
- These autoantibodies significantly inhibited α-Syn fibril formation and reversed α-Syn oligomer-induced toxicity in SH-SY5Y cells.
Conclusions:
- Naturally occurring autoantibodies against α-Syn possess significant binding and functional capabilities.
- These autoantibodies interfere with key pathological events in Parkinson's disease, including fibril formation and toxicity.
- α-Syn-nAbs represent a promising candidate for the development of novel Parkinson's disease therapeutics.
Related Concept Videos
03:03Amyloid Fibrils
10.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
10.2K
01:29Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28